These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia. Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255 [TBL] [Abstract][Full Text] [Related]
3. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147 [TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603 [TBL] [Abstract][Full Text] [Related]
5. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions. Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Abdel-Qadir H; Sabrie N; Leong D; Pang A; Austin PC; Prica A; Nanthakumar K; Calvillo-Argüelles O; Lee DS; Thavendiranathan P J Clin Oncol; 2021 Nov; 39(31):3453-3462. PubMed ID: 34464154 [TBL] [Abstract][Full Text] [Related]
9. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients. Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672 [TBL] [Abstract][Full Text] [Related]
10. Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Huntington SF; de Nigris E; Puckett JT; Kamal-Bahl S; Farooqui M; Ryland K; Sarpong EM; Leng S; Yang X; Doshi JA Cancer Med; 2024 Jan; 13(2):e6953. PubMed ID: 38348963 [TBL] [Abstract][Full Text] [Related]
11. Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration. Walker C; Horowitz A; Nooruddin Z; Frei CR J Oncol Pharm Pract; 2024 Jun; 30(4):673-677. PubMed ID: 37309168 [TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Gordon MJ; Jones JE; George B; Peterson C; Burger JA; Jain N; Keating M; Wierda WG; Durand JB; Ferrajoli A Cancer; 2023 Jul; 129(14):2192-2200. PubMed ID: 37016930 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data. Tombak A; Pepedil Tanrıkulu F; Durusoy SS; Dinçyürek HD; Kaya E; Ümit EG; Yavaşoğlu İ; Mehtap Ö; Deveci B; Özcan MA; Terzi H; Okay M; Sayınalp N; Yılmaz M; Okan V; Kızıklı A; Özcan Ö; Çetin G; Demircioğlu S; Aydoğdu İ; Saydam G; Davulcu EA; İlhan G; Uçar MA; Özet G; Akpınar S; Turgut B; Berber İ; Kurtoğlu E; Sönmez M; Batur DS; Yıldırım R; Özkocamaz V; Güneş AK; Sahip B; Ertop Ş; Akay OM; Baştürk A; Doğu MH; Akdeniz A; Ünal A; Seyhanlı A; Gürkan E; Çekdemir D; Ferhanoğlu B Turk J Haematol; 2021 Dec; 38(4):273-285. PubMed ID: 34448556 [TBL] [Abstract][Full Text] [Related]
14. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Langerbeins P; Zhang C; Robrecht S; Cramer P; Fürstenau M; Al-Sawaf O; von Tresckow J; Fink AM; Kreuzer KA; Vehling-Kaiser U; Tausch E; Müller L; Eckart MJ; Schlag R; Freier W; Gaska T; Balser C; Reiser M; Stauch M; Wendtner CM; Fischer K; Stilgenbauer S; Eichhorst B; Hallek M Blood; 2022 Jan; 139(2):177-187. PubMed ID: 34758069 [TBL] [Abstract][Full Text] [Related]
15. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Stephens DM; Byrd JC Blood; 2019 Mar; 133(12):1298-1307. PubMed ID: 30642919 [TBL] [Abstract][Full Text] [Related]
16. Ibrutinib dose modifications in the management of CLL. Hardy-Abeloos C; Pinotti R; Gabrilove J J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582 [TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410 [TBL] [Abstract][Full Text] [Related]
19. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258 [TBL] [Abstract][Full Text] [Related]
20. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study. Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525 [No Abstract] [Full Text] [Related] [Next] [New Search]